Published in Vaccine Weekly, July 27th, 1998
In the study, 10 patients with recurrent malignant gliomas were treated by adoptive immunotherapy, an intravenous infusion of their own activated immune cells. Three patients had reduction in tumor size lasting at least six months. The patients also demonstrated a survival advantage. The typical length of survival following a recurrence of malignant gliomas is five months, while the median survival...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly